The 8 analysts offering 12-month price forecasts for Enanta Pharmaceuticals Inc have a median target of 65.00, with a high estimate of 117.00 and a low estimate of 44.00. The median estimate represents a +47.33% increase from the last price of 44.12.
The current consensus among 8 polled investment analysts is to Buy stock in Enanta Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.92
Reporting Date Nov 30
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.